ZyVersa Therapeutics, Inc., a biopharmaceutical company, has been the subject of an amended Schedule 13G/A filing with the U.S. Securities and Exchange Commission (SEC) on December 31, 2023. The amendment was filed by a group of reporting persons including Ionic Ventures LLC, Ionic Management LLC, and individuals Brendan O'Neil and Keith Coulston. The filing indicates that these reporting persons have collectively ceased to be the beneficial owners of more than five percent of ZyVersa's outstanding common stock. The shares in question, totaling 52,026, are issuable upon the full exercise of common stock purchase warrants. This amendment serves as an exit filing for the reporting persons, who have updated their beneficial ownership information and amended certain items from the original Schedule...Show More

ZyVersa Therapeutics, Inc., a biopharmaceutical company, has been the subject of an amended Schedule 13G/A filing with the U.S. Securities and Exchange Commission (SEC) on December 31, 2023. The amendment was filed by a group of reporting persons including Ionic Ventures LLC, Ionic Management LLC, and individuals Brendan O'Neil and Keith Coulston. The filing indicates that these reporting persons have collectively ceased to be the beneficial owners of more than five percent of ZyVersa's outstanding common stock. The shares in question, totaling 52,026, are issuable upon the full exercise of common stock purchase warrants. This amendment serves as an exit filing for the reporting persons, who have updated their beneficial ownership information and amended certain items from the original Schedule 13G filed on May 3, 2023. The reporting persons have entered into a Joint Filing Agreement, indicating that they will file jointly for any subsequent amendments. The principal business address for the reporting persons is in San Francisco, California, and the shares reported are based on 1,243,297 outstanding shares of ZyVersa's common stock as disclosed in the company's prospectus filed with the SEC on December 8, 2023.